Updates and Developments in Oncology
2006
Targeting TGF-β to Improve Cancer Immunotherapy
publication
Evidence: moderate
Author Information
Author(s): Hahn T. PhD, Akporiaye E.T. PhD
Primary Institution: University of Arizona
Hypothesis
Can targeting transforming growth factor β (TGF-β) enhance the effectiveness of cancer immunotherapy?
Conclusion
Therapeutic strategies that neutralize TGF-β significantly enhance the immune response against tumors.
Supporting Evidence
- TGF-β is secreted in large amounts by cancer cells and is linked to disease progression.
- TGF-β inhibits the function of immune cells, including dendritic cells and T cells.
- Strategies that neutralize TGF-β have shown promise in enhancing immune responses in animal models.
Takeaway
This study suggests that blocking a substance called TGF-β can help the body's immune system fight cancer better.
Methodology
The study discusses various strategies to inhibit TGF-β signaling in immune cells and their potential to enhance cancer immunotherapy.
Limitations
The findings from animal models may not directly translate to human therapies.
Want to read the original?
Access the complete publication on the publisher's website